Show simple item record

dc.contributor.authorRoblin, P M
dc.contributor.authorDumornay, W
dc.contributor.authorHammerschlag, M R
dc.date.accessioned2023-06-30T15:59:46Z
dc.date.available2023-06-30T15:59:46Z
dc.date.issued1992-08
dc.identifier.citationRoblin PM, Dumornay W, Hammerschlag MR. Use of HEp-2 cells for improved isolation and passage of Chlamydia pneumoniae. J Clin Microbiol. 1992 Aug;30(8):1968-71. doi: 10.1128/jcm.30.8.1968-1971.1992. PMID: 1500500; PMCID: PMC265424.en_US
dc.identifier.issn0095-1137
dc.identifier.pmid1500500
dc.identifier.urihttp://hdl.handle.net/20.500.12648/10331
dc.description.abstractChlamydia pneumoniae has proved to be difficult to isolate and propagate in cell culture. We compared the growth of three strains of C. pneumoniae, TW-183 and two clinical isolates from Brooklyn, N.Y., in five cell lines, including HeLa 229, McCoy, HL, HEp-2, and HTED, an immortalized human tracheal cell line. HEp-2 was the most sensitive cell line tested. When 10-fold dilutions of three C. pneumoniae strains at known titers were inoculated into the different cell lines, the mean number of inclusion-forming units per milliliter was 1 to 2 log units higher in the HEp-2 than in the other cell lines. This difference was statistically significant. Omission of pretreatment with DEAE-dextran resulted in larger inclusions than those seen in pretreated cells, with the exception of McCoy and HTED cells. Retrieval of clinical specimens previously cultured on HeLa 229 cells and comparison of mean inclusion counts in fresh clinical specimens simultaneously inoculated on HeLa 229 and HEp-2 cells suggested that culture in HEp-2 cells may require only the initial inoculation and one passage, compared with three to four passages, as required by culture in HeLa 229 cells.
dc.language.isoenen_US
dc.relation.urlhttps://journals.asm.org/doi/epdf/10.1128/jcm.30.8.1968-1971.1992en_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleUse of HEp-2 cells for improved isolation and passage of Chlamydia pneumoniae.en_US
dc.typeArticle/Reviewen_US
dc.source.journaltitleJournal of clinical microbiologyen_US
dc.source.volume30
dc.source.issue8
dc.source.beginpage1968
dc.source.endpage71
dc.source.countryUnited States
dc.description.versionVoRen_US
refterms.dateFOA2023-06-30T15:59:47Z
html.description.abstractChlamydia pneumoniae has proved to be difficult to isolate and propagate in cell culture. We compared the growth of three strains of C. pneumoniae, TW-183 and two clinical isolates from Brooklyn, N.Y., in five cell lines, including HeLa 229, McCoy, HL, HEp-2, and HTED, an immortalized human tracheal cell line. HEp-2 was the most sensitive cell line tested. When 10-fold dilutions of three C. pneumoniae strains at known titers were inoculated into the different cell lines, the mean number of inclusion-forming units per milliliter was 1 to 2 log units higher in the HEp-2 than in the other cell lines. This difference was statistically significant. Omission of pretreatment with DEAE-dextran resulted in larger inclusions than those seen in pretreated cells, with the exception of McCoy and HTED cells. Retrieval of clinical specimens previously cultured on HeLa 229 cells and comparison of mean inclusion counts in fresh clinical specimens simultaneously inoculated on HeLa 229 and HEp-2 cells suggested that culture in HEp-2 cells may require only the initial inoculation and one passage, compared with three to four passages, as required by culture in HeLa 229 cells.
dc.description.institutionSUNY Downstateen_US
dc.description.departmentPediatricsen_US
dc.description.degreelevelN/Aen_US
dc.identifier.journalJournal of clinical microbiology
dc.identifier.issue8en_US


Files in this item

Thumbnail
Name:
jcm.30.8.1968-1971.1992.pdf
Size:
855.9Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International